The remaining tumors were classified as negative.2 However, the published results of the DESTINY-Breast04 phase 3 trial demonstrated the efficacy of anti-ERBB2 antibody-drug conjugate trastuzumab-deruxtecan in patients with ERBB2-low metastatic BC. The gene discussed is ERBB2; the disease is breast cancer.